Objective:Objective: The objective of this study was to compare two different intensities of vitamin KK antagonists (VKA) among patients with mechanical heart valves using meta-analytic techniques. .
INTRODUCTION N
Patientss with mechanical heart valves are at increased risk for valve thrombosis and systemicc embolism, predominantly stroke. The incidence rates of these serious complicationss can be reduced by vitamin K antagonist (VKA) therapy and life-long anticoagulationn is recommended in patients with mechanical heart valves. However, life-longg anticoagulant therapy is associated with a risk of severe and sometimes fatal bleeding.. The relation between preventing thromboembolism and introducing bleeding complicationss is represented by an U-shaped relation between the intensity of VKA and thee risk of thromboembolic -and bleeding events. The optimal VKA intensity, therefore, definedd as the intensity at which the incidence of both thromboembolic as well as bleedingg complications is lowest, is a delicate equilibrium. The first ACCP guidelines publishedd in 1986 recommended an INR between 3.0 and 4.5, regardless of the positionn of the valve 12 . In 1995 Cannegieter et al. described, based on a discrepancy betweenn targeted and achieved INR, the relation between the effectiveness of anticoagulationn and the actually achieved intensities 3 . The study showed that the optimall intensity of anticoagulation, resulting in the fewest adverse events, lies between INRR levels of 2.5 to 4.9. The incidence of the events rises sharply above or below this range.. As a target range, they recommended an INR of 3.0 to 4.0 for both aortic and mitrall valves, although it was shown that the risk of thromboembolic complications appearss to vary with the position of the valve. Patients with a prosthesis in the mitral positionn have a significantly higher risk of thromboembolic complications than those withh an aortic valve prosthesis 4 . Based on this discrepancy, more recently, a minor discriminationn in anticoagulation intensity was recommended between aortic and mitral valvess and the target range was lowered to 2.0 and 3.5 5 , depending on the position and typee of the valve. These latest guidelines, however, are based on only a few studies.
Thus,, the range of optimal intensity of VKA is an ongoing matter of debate, moreover sincee it is difficult to assess the individual risk of thromboembolism and bleeding in a individuall patient. To obtain reliable estimates on the adverse events and to make guideliness for daily clinical practice we performed an extended analysis of all published studiess with data on the incidence of thromboembolic and bleeding events in patients withh a mechanical heart valve in either the aortic or the mitral position during different intensitiess of VKA therapy.
METHODS S

SelectionSelection of articles
AA computerized search in Pubmed database over the period January 1965 to June 2002 wass performed to retrieve studies with data on the incidences of thromboembolic and bleedingg complications in patients with mechanical heart valve prostheses. The key wordss used were: heart valve prosthesis, mechanical heart valve, anticoagulants, coumarin,, warfarin, thromboembolism and hemorrhage. Subsequently, a manual searchh of the reference lists from the retrieved articles was done to identify additional articles.. Only studies which met the following criteria were included: 1) possibility to differentiatee between aortic valve prosthesis and mitral valve prosthesis, 2) specificationn of the target INR or prothrombin time of VKA-therapy, 3) no change in the targett INR or prothrombin time ratio during follow up, 4) thromboembolic and bleeding eventss classified according to Edmunds et al 6 or otherwise adequately classified and 5) meann age of the patients older than 18 years. Studies were excluded when: 1) the numberr of patients lost to follow up was larger than 5%, 2) the study included bioprosthesess or caged-ball valves, 3) the patients received antiplatelet therapy alone or antiplatelett therapy in combination with VKA and 4) the cohort was the same as reportedd in another included study.
DataData extraction
Alll potentially eligible articles were evaluated independently by two reviewers. Data on thee position and type of the prosthetic valve, target INR or prothrombin time ratio, numberr of patients and patient-years were extracted from each study. The outcome eventss of interest included valve thrombosis, systemic embolism and bleeding. A data formm was used to collect this information. Disagreements were resolved by consensus.
OutcomeOutcome events
Thee events were analysed according to the guidelines for reporting morbidity and 
Subgroups Subgroups
Wee separately analysed studies with aortic and mitral valve prostheses. These studies weree subdivided into low intensity VKA therapy or high intensity VKA therapy. Low 
StatisticalStatistical analysis
Forr each outcome event and per study separately, an annual incidence (number of outcomee events divided by the number of patient-years) and its standard error was caicuiated.. in case the number of events was zero, a statistical correction for the standardd error was made by adding a fictive number of 0.5 events to the number of eventss and to the number of patient-years. The significant Chi-square test for each outcomee result may implicate heterogeneity between the studies. Therefore we did not usee the fixed effect method, but the random effect method. Since study size would have smalll effect in a random effect model, the calculated incidences were averaged by addingg the yearly incidence rates of all studies divided by the number of studies. Ninetyfivee percent confidence intervals (CI) of rate ratios were calculated with the assumption off a Poisson distribution. Statistical significance between the incidences of two groups wass calculated using the Wald test. A p-value less then 0.05 (two-sided) was considered too be statistically significant.
RESULTS S
Studies Studies
Thee literature search identified 141 potentially eligible articles. Of these 141 articles, 35
couldd be included in the analysis. Reasons for exclusion were: inability to differentiate betweenn aortic and mitral valves (23 studies), intensity of oral anticoagulant therapy wass not specified (27 studies), the use of antiplatelet therapy (14 studies), the events or patient-yearss were not specified (18 studies), the cohort was the same as another includedd study (8 studies), lost to follow up not specified or exceeding 5% (6 studies), or otherr reasons (10 studies). The list of excluded articles will appear in the online appendixx for this article (www.cardiosource.com/JACC.html). 
HighHigh vs. low intensity VKA therapy in patients with aortic valve prostheses
Thee incidence rates of valve thrombosis, thromboembolism and bleeding for high and loww intensity VKA therapy in patients with an aortic valve prosthesis are shown in Table   III 
HighHigh vs. low intensity VKA therapy in patients with mitral valve prostheses
Thee results of the analysis in the group of patients with a prosthetic mitral valve are listedd in Table IV Legendd to Tables III and IV VTT = valve thrombosis; TE = thromboembolism; VT+TE= all valve thrombosis and thromboembolism: Hemorr = hemorrhage; CI = confidence interval; All= all thromboembolic and bleeding events
AorticAortic versus mitral valve prostheses
Thee number of valve thrombosis and thromboembolic events is significantly lower in the aorticc valve group compared with the mitral valve group for both low and high intensity VKAA therapy. The risk ratios are shown in Table V . Treatment with high intensity therapy 43 3 givee rise to a significant increase in bleeding events in patients with a prosthetic aortic valvee as compared to patients with a mitral valve (risk ratio = 1.15, 95% CI 1.06-1.25).
Noo difference in bleeding complications was observed between patients with aortic and mitrall valves treated with low intensity VKA (risk ratio = 1.01, 95% CI 0.94-1.07). The totall number of events (thromboembolism and bleeding) for both high and low intensity treatmentt was lower in the aortic valve group than for patients in the mitral valve group Thee incidence of valve thrombosis and thromboembolism is higher in patients with mitrall valve prostheses than with aortic valve prostheses for both low and high intensity VKAA therapy. This is presumably due to different bloodflow properties over the mitral valvee as compared to the aortic valve and the relatively increased incidence of atrial fibrillationn in patients with mitral valve heart disease.
Theree are a few limitations of the present study. First, most reports used for this analysiss are based on an intention to treat INR range, and therefore information on the actuallyy achieved intensity of VKA treatment and the compliance of therapy was lacking.
Thee time spent in the therapeutic range is approximately 50-70% in well designed cohorts 466 and it is unlikely that the achieved INR range in our study-population will exceedd this percentage. Since most of the adverse events occur in the period of underorr overcoagulation, it is plausible to assume that the risk for embolism and bleeding will 45 5 decreasee with a more stable level of anticoagulation. In addition, a major effect of anticoagulationn control on the long-term survival was shown in a recent study 47 AA second limitation may be that most of the included studies were cohort series, withoutt a control group. These cohort studies, however, allow for the estimate of the absolutee risk of bleeding and thrombosis. This pooled analysis of 35 studies, with in totall more than 23.000 patients who were followed for more than 100.000 patientyears,, indeed yielded sufficient power to detect significant differences in favour of high intensityy VKA therapy. To minimize the risk for bias, we only selected studies wherein all thee adverse events were classified according to a international accepted scoring system. Anotherr limitation is that some studies used older valve types. However, most valvee types used in the analysis are still being used for insertion nowadays.
Totall mortality would be an important outcome in this analysis. Unfortunately, fromm the majority of the studies used for the analysis, no data on mortality could be retrievedd to be able to estimate a reliable mortality rate.
Ourr recommendations are based on data derived from patients with a mean age att valve implantation of 55 years. Since there is a trend towards valve replacements in olderr age groups and the fact that older patients have an increased bleeding risk 3 , it's uncertainn whether this group of patients will benefit from high intensity VKA therapy.
However,, in our analysis we were not able to identify age-associated risks, since most of thee studies only report on age as a baseline characteristic. wass as effective as VKA (INR 3.5-4.5) alone. The results from these studies cannot be 46 6 consideredd as sufficient evidence for recommending combination therapy. In exceptionall cases of patients with thromboembolic complications despite adequate VKA therapy,, the addition of antiplatelet therapy can be considered for the prevention of thromboembolicc events.
Inn conclusion, this analysis shows that both patients with aortic and mitral valve willl benefit from high intensity VKA therapy, with a target INR above 3.0. For daily practice,, we recommend an INR between 3.0 and 4.5. Since aortic valve prosthesis are consideredd less thrombogenic than prosthesis in the mitral position, a target INR at the lowerr side of this range is advised for aortic valves, whereas a target INR at the upper sidee of this range is suggested for mitral valves. However, a prospective study that addresss both the intensity of VKA and the position of the mechanical heart valve are definitelyy needed before the discussion can be resolved. 
APPENDIX X
ListList of excluded articles-.
--Inability to differentiate between aortic and mitral valves 123 --Intensity of oral anticoagulant therapy was not specified 24~50 --The events or patient-years were not specified 5168 --The use of antiplatelet therapy 69 82 --The cohort was the same as another included study 83 " 90 --Lost to follow up not specified or exceeding 5%
9196
-Otherr reasons 97106
